Shepherd Financial Partners LLC Takes $656,000 Position in Boston Scientific Corporation $BSX

Shepherd Financial Partners LLC bought a new stake in Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,362 shares of the medical equipment provider’s stock, valued at approximately $656,000.

Other institutional investors have also added to or reduced their stakes in the company. Kelleher Financial Advisors bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $25,000. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific in the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific in the 4th quarter valued at $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific in the 1st quarter valued at $28,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BSX shares. TD Cowen lowered their price objective on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Wolfe Research cut shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Argus restated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Finally, UBS Group dropped their price target on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Activity at Boston Scientific

In other news, Director David C. Habiger acquired 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Edward J. Ludwig bought 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 194,522 shares of company stock valued at $9,385,210 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Trading Up 3.1%

NYSE BSX opened at $52.02 on Thursday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The business has a fifty day simple moving average of $46.22 and a 200 day simple moving average of $58.22. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The firm has a market capitalization of $75.39 billion, a P/E ratio of 21.06, a PEG ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the firm earned $0.75 EPS. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.